Investigating the role of prognostic mitophagy-related genes in non-small cell cancer pathogenesis via multiomics and network-based approach
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Researchers identified TDRKH as a potential prognostic biomarker for lung adenocarcinoma (LUAD). This gene
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Lung cancer, particularly non-small cell lung cancer (NSCLC), is a leading malignancy with significant molecular heterogeneity.
- Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are the main subtypes of NSCLC.
Purpose Of The Study
- To identify differentially expressed mitophagy-related genes (DEMRGs) in LUAD and LUSC.
- To discover novel prognostic biomarkers for LUAD through integrated bioinformatic and experimental analyses.
Main Methods
- Extraction of mRNA count data from public databases.
- Identification of differentially expressed genes (DEGs) and DEMRGs.
- Clustering, enrichment, survival, and mutational analyses of DEMRGs.
- Validation of potential biomarkers using immunohistochemistry (IHC) and semi-quantitative PCR.
Main Results
- Identified 986 DEGs in LUAD and 1714 DEGs in LUSC.
- Discovered 7 significant DEMRGs across both cohorts.
- The gene TDRKH showed significant association with overall survival (OS) in LUAD patients.
- TDRKH exhibited 14% amplification in LUAD and was validated experimentally.
Conclusions
- TDRKH emerges as a promising prognostic biomarker for LUAD.
- Genetic alterations in TDRKH warrant further investigation for targeted therapy and early diagnostics in LUAD.
- Findings support the exploration of TDRKH in precision oncology for lung adenocarcinoma.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...